Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TRPV3 | Q8NET8 | 9/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12616291 | 0.86 | KDM1A (0.42) | KDM1AMAOAMAOBTRPV3SIRT2 | |
| SCHEMBL5343292 | 0.83 | TRPV3 (0.46) | KDM1AMAOAMAOBTRPV3SIRT2 | |
| SCHEMBL30232895 | 0.82 | KDM1A (0.42) | KDM1AMAOAMAOBTRPV3SIRT2 | |
| SCHEMBL3730227 | 0.82 | CASR (0.50) | KDM1AMAOAMAOBTRPV3SIRT2 | |
| SCHEMBL3730225 | 0.82 | CASR (0.50) | KDM1AMAOAMAOBTRPV3SIRT2 | |
| SCHEMBL23015676 | 0.81 | TRPV3 (0.40) | TRPV3NPSR1CXCR4BCHEACHE | |
| SCHEMBL5343914 | 0.80 | TRPV3 (0.64) | TRPV3 | |
| SCHEMBL12538333 | 0.80 | TRPV3 (0.64) | TRPV3 | |
| SCHEMBL3512286 | 0.80 | SIRT2 (0.40) | KDM1AMAOAMAOBTRPV3SIRT2 | |
| SCHEMBL12259282 | 0.79 | SMN1; SMN2 (0.49) | KDM1AMAOAMAOBTRPV3NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8729271-B2 | Glycine transporter inhibiting substances | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2014-05-20 | — | — | US | disclosed |
| EP-2617715-A1 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-20130184460-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2013-07-18 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1483263-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | Amgen Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| WO-2003070727-A1 | THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER | AMGEN INC. (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | KDM1A 2930/4885MAOA 3942/4885MAOB 3362/4885 |
| US-20130184460-A1 | GLYCINE TRANSPORTER INHIBITING SUBSTANCES | SLC1A2, SLC18A2, SLC6A1 | KDM1A 4495/4885MAOA 393/4885MAOB 240/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | KDM1A 2930/4885MAOA 3942/4885MAOB 3362/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | KDM1A 2930/4885MAOA 3942/4885MAOB 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.